Abstract: A vehicle moving apparatus may include a housing extending in a first direction; an elevator coupled to the housing to be movable in the first direction and another direction opposite thereto, extending in a third direction and being inserted to be drawable into an underside space of a vehicle, and configured to lift or lower a wheel of the vehicle; and a wheel assembly coupled to the elevator and configured to move the housing and the elevator in a direction toward the vehicle or in a direction opposite the vehicle, wherein the wheel assembly includes a wheel rotatably provided with a vertical direction as an axis, and configured to movably support the elevator; and an actuator coupled to the wheel and configured to provide power for rotating the wheel, wherein the wheel is rotatable such that a diameter of the wheel is aligned between the first and third directions.

Abstract: A method of manufacturing a display device includes aligning light emitting elements in an emission area on a substrate, depositing an indium-tin alloy on an entire surface of the substrate at room temperature, heat-treating the indium-tin alloy to reflow along side surfaces of each of the light emitting elements, heat-treating the indium-tin alloy in an oxygen atmosphere to form indium tin oxide, and etching the indium tin oxide to form a first pixel electrode contacting first ends of at least a portion of the light emitting elements.

Abstract: The present invention relates to a novel heterocyclic compound usable in an organic light-emitting device and to an organic light-emitting device comprising same, wherein [chemical formula A] is as described in the detailed description of the invention.

Abstract: Disclosed herein relates to an electrode for a lithium secondary battery and a manufacturing method thereof, and since the electrode for a lithium secondary battery is provided with an auxiliary coating layer containing inorganic particles, a phenolic compound, and a binder at the end of an electrode mixture layer containing an electrode active material, thereby improving energy density of the battery due to an improvement in thickness deviation at the end of the electrode mixture layer, and preventing lithium from being precipitated at the end of the electrode, especially the negative electrode, due to increase in the adhesive strength of the separator at the end of the electrode, it has an advantage of excellent safety.

Abstract: The present invention provides a novel compound represented by Chemical Formula 2, or a pharmaceutically acceptable salt thereof. The novel compound according to the present invention exhibits an excellent acid secretion inhibitory effect.

Abstract: The present invention provides a novel compound represented by Chemical Formula 2, or a pharmaceutically acceptable salt thereof. The novel compound according to the present invention exhibits an excellent acid secretion inhibitory effect.

Abstract: Provided are an improved culture process for reducing unwanted culture byproducts when a target protein is produced in a glutamine-free cell culture medium, an improved culture process for producing a target protein in a glutamine-free cell culture medium, or an improved culture process for producing a target protein in a glutamine-free cell culture medium.

Abstract: The present invention provides a novel compound represented by Chemical Formula 2, or a pharmaceutically acceptable salt thereof. The novel compound according to the present invention exhibits an excellent acid secretion inhibitory effect.

Abstract: HTS screening was performed regarding cell proliferation, one of symptoms of senescence. As a result, KB1541, which was the most effective on cell proliferation, was earned. The present invention described how the compound regulates cell proliferation and senescence. The present invention uncovered what proteins interacted with the compound using streptavidin-magnetic beads after treating with biotin-connected KB1541. Consequently, it was identified that mitochondrial proteins interacted with the compound. In ATP assay, electron microscope and IP assay, the inventors identified that the compound regulated mitochondrial proteins and thereby increased ATP production as well as recovered senescence.

Abstract: The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.

Abstract: The present invent ion relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.

Abstract: The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.

Abstract: The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.

Abstract: Disclosed are a novel 5-membered heterocycle derivatives of Formula I, a tautomer, pharmaceutically acceptable salt, prodrug thereof and a pharmaceutical use thereof. The 5-membered heterocycle derivatives of Formula I, a tautomer, pharmaceutically acceptable salt, prodrug thereof and compositions containing them are useful for treating a tumor.

Abstract: The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.